SCHEMBL6798334

SCHEMBL6798334

COC(=O)c1cccc(Oc2ncccn2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.72
KMT2A Q03164 2/20 0.72
HTT P42858 2/20 0.59
GAA P10253 1/20 0.59
MAPT P10636 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.54
TP53 P04637 2/20 0.54
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
POLB P06746 1/20 0.51
BLM P54132 1/20 0.51
PKM P14618 2/20 0.50
ALOX15 P16050 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
MAPK1 P28482 1/20 0.50
MET P08581 1/20 0.49
ALK Q9UM73 1/20 0.49
CYSLTR1 Q9Y271 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980743 0.85 MEN1 (0.54) MEN1KMT2AHTTGAAMAPT
SCHEMBL2436534 0.85 L3MBTL1 (0.65) MEN1KMT2AL3MBTL1SMN1; SMN2TP53
SCHEMBL6798209 0.82 KMT2A (0.73) MEN1KMT2AHTTGAAMAPT
SCHEMBL29720129 0.82 KMT2A (0.73) MEN1KMT2AHTTGAAMAPT
SCHEMBL5558318 0.82 SMN1; SMN2 (0.66) MEN1KMT2AHTTMAPTL3MBTL1
Methyl 3-Methoxybenzoate SCHEMBL384913 0.81 SMN1; SMN2 (0.73) MEN1KMT2AHTTMAPTSMN1; SMN2
Methyl 3-Methoxybenzoate SCHEMBL29702092 0.81 SMN1; SMN2 (0.73) MEN1KMT2AHTTMAPTSMN1; SMN2
SCHEMBL8603505 0.81 MEN1 (0.72) MEN1KMT2AHTTGAAMAPT
SCHEMBL6243390 0.81 L3MBTL1 (0.58) MEN1KMT2AHTTL3MBTL1SMN1; SMN2
SCHEMBL521860 0.80 AKR1C3 (0.68) MEN1KMT2AMAPTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727245-B2 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-27 US disclosed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 EP disclosed
US-20020107251-A1 Heterobicyclic derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 US disclosed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 US disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 EP disclosed
EP-0770079-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-05-02 EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107251-A1 Heterobicyclic derivatives ARSA, ARRB1, SULT2A1 MEN1 2703/4885KMT2A 968/4885HTT 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.